xp-102
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05275374)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCCS(=O)(=O)Nc1ccc(F)c(-n2cc(-c3cncnc3)c3nc(N(C)C4CCN(CC)CC4)ccc32)c1F- Mol. weight
- 569.68 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4212692 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05275374 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Xynomic Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xynomic Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1